Protalix BioTherapeutics, Inc.
PLX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001006281
No open-market purchases or sales by Protalix BioTherapeutics, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $33.7M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Protalix BioTherapeutics, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 66 | 64 | −2 |
| Shares | 9.86M | 9.39M | −474.8K (−4.8%) |
| Value | $17.6M | $11.9M | −$5.64M (−32.1%) |
New holders (8)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 157,516 | $198.0K | 0.02% |
| Citadel Advisors LLC | 37,788 | $47.6K | 0.00% |
| Verition Fund Management LLC | 23,465 | $29.6K | 0.00% |
| Squarepoint Ops LLC | 17,815 | $22.4K | 0.00% |
| Millennium Management LLC | 10,484 | $13.2K | 0.00% |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 9 | $11 | 0.00% |
| Simplex Trading, LLC | 459 | $0 | 0.00% |
| CWM, LLC | 6 | $0 | 0.00% |
Sold out (10)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Denali Advisors LLC | 94,700 | $168.6K |
| Connor, Clark & Lunn Investment Management Ltd. | 70,990 | $126.4K |
| Bailard, Inc. | 68,100 | $121.2K |
| Sculptor Capital LP | 37,000 | $65.9K |
| Two Sigma Investments, LP | 19,600 | $34.9K |
| XTX Topco Ltd | 18,750 | $33.4K |
| State Board of Administration of Florida Retirement System | 17,228 | $30.7K |
| Manufacturers Life Insurance Company, The | 10,514 | $18.7K |
| Advisory Services Network, LLC | 100 | $178 |
| The PNC Financial Services Group, Inc. | 19 | $34 |